Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
10. April 2024
1 min to read

Artificial intelligence-based detection of occlusion myocardial infarction: first external validation in a German chest-pain unit cohort

Overview:

In a large-scale retrospective validation involving over 1,700 consecutive patients presenting to German Chest Pain Units, the PMcardio STEMI AI ECG Model demonstrated high diagnostic accuracy (95.3%) and specificity (96.7%) in identifying high-risk patients typically missed by standard ECG interpretation. This highlights its potential to significantly improve emergency care through earlier detection and intervention in a real-world, broad clinical setting.

Presented at: German Society for Cardiology (DGK) 90th Annual Congress
Presented Date: April 10, 2024

Background

Occlusion myocardial infarction (OMI) might be missed by conventional ST-elevation myocardial infarction (STEMI) criteria on 12-lead surface electrocardiogram (ECG). Twenty-five percent of non-STEMI patients have OMI in worldwide registries. These patients are at risk for delayed invasive management resulting in poor short- and long-term prognosis. 

Artificial intelligence (AI) model studies have shown robust performance in detecting angiographically determined OMI using individual 12-lead surface ECGs. However, these studies were conducted in high-risk patient populations with a high prevalence of OMI and more data is needed to evaluate the utility of AI in a broader chest pain (CP) population.

We investigated the performance of an AI ECG model detecting angiographic OMI in a German metropolitan chest pain unit (CPU) cohort of all-comer patients without typical STEMI criteria from a tertiary care center.

Methods

The AI model was developed and validated in international cohorts including >12,000 CP patients with an OMI prevalence of around 20%. The present study included all consecutive patients presenting to CPU who were either ruled out by serial high-sensitive cardiac troponin T (hs-cTnT) testing or referred for angiography after CPU assessment.

STEMI patients diagnosed in the prehospital phase were excluded from the analysis (Figure 1). In Germany, peak troponin is not routinely measured. Consequently, an angiographic OMI outcome was modeled including identification of culprit lesion, coronary artery flow and hs-cTnT.

The AI model performance was assessed according to sensitivity, specificity, accuracy and predictive values in the overall cohort and in the subgroup of ruled-out population following 0/1h hs-cTnT algorithm. Receiver operating characteristic (ROC) analyses were performed.

Results

In total, 1776 ECGs from 1770 CPU patients were considered. The mean age of patients was 53.2 (±18.9) years, and 62.1% were male. Eighty percent of patients were ruled-out by serial hs-cTnT measurement, and the remaining 354 patients were referred for invasive management.

OMI prevalence was 3.16%. In the overall analysis, the AI ECG model achieved an area under the curve of 0.894 in identifying OMI (Figure 2 and table 1). Sensitivity was 0.518 (95% CI: 0.386-0.649), and specificity reached 0.967 (95% CI: 0.959-0.976). Correspondingly, negative predictive value (NPV) was 98.4% (95% CI: 97.8-99.0), and positive predictive value (PPV) was 34.1% (24.2-44.4). Diagnostic accuracy was 0.953 (95% CI: 0.943-0.963).

Subgroup analysis of patients ruled-out following 0/1h hs-cTnT algorithm identified misclassification as false-positive in 1% of ECGs by AI model. Specificity and accuracy both were 0.989 (95% CI: 0.983-0.994, see table 2). Negative predictive value was 100% (95% CI: 100-100).

Conclusion

This external validation study of a pre-existing in AI ECG model demonstrates remarkable diagnostic accuracy in a German CPU cohort without a pre-clinical diagnosis of STEMI. The AI model was reliable with high specificity and resulted in overcalls only in few cases.

Sensitivity analysis of the AI ECG model was restricted by the low prevalence of OMI and by the modeled OMI definition given the German CPU specifics. The present study proved technical feasibility, but future studies are required to further evaluate its applicability in German CPUs.


Authors: Sascha Macherey-Meyer (Köln), P. Meyers (Charlotte, NC), S. Smith (Minneapolis), F. Hundehege (Köln), L. Krücken (Köln), S. Heyne (Köln), M. Meertens (Mainz), S. Braumann (Köln), V. Mauri (Köln), S. Baldus (Köln), S. Lee (Köln), C. Adler (Köln)

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

AI-Enabled ECG Analysis Improves Diagnostic Accuracy and Reduces False STEMI Activations: A Multicenter U.S. Registry

In a large, multi-center evaluation presented as Late-Breaking Science at the TCT 2025 conference, investigators assessed the diagnostic accuracy of the Queen of Hearts™ AI algorithm for ST-segment elevation myocardial infarction (STEMI) detection in emergency care. The study compared AI-enhanced ECG interpretation against standard triage protocols across three U.S. PCI centers, encompassing more than 1,000 patients who activated emergent reperfusion pathways. Published in JACC: Cardiovascular Interventions, the results demonstrated significantly improved accuracy and reduced false activations when using AI-driven analysis.

Electrocardiographic Diagnostic Possibilities for Atrial Fibrillation Using Artificial Intelligence: Differentiation from Sinus Rhythm and Other Arrhythmias with the Pmcardio App in Covid-19 Patients

This study evaluated how effectively artificial intelligence can detect atrial fibrillation (AF) in COVID-19 patients using ECG analysis. Researchers compared the PMcardio AI application’s performance with that of cardiologists and infectious disease specialists. Among 116 hospitalized COVID-19 patients, PMcardio achieved perfect diagnostic accuracy (sensitivity and specificity of 1.00) for AF detection, matching cardiologists and surpassing infectious disease specialists. The AI’s performance remained consistent across confidence levels, and its severity assessments correlated significantly with rhythm findings. These results highlight AI’s potential to improve arrhythmia detection, streamline care, and reduce unnecessary in-person evaluations during infectious disease outbreaks.

Join over 100,000 healthcare professionals who are already taking advantage of AI